Catalyst

Slingshot members are tracking this event:

FDA Rolling Submission of Olaratumab Expected to be Complete By End of H1 of 2016

Source Link:
http://files.shareholder.com/downloads/LLY/1486572605x8064597x871994/375E180E-36E6-48F0-8503-C8D1D5DD9947/Lilly_Q4_2015_Slides.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
LLY
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Recently, Lilly initiated the rolling submission of Olaratumab to the FDA.  The submission is expected to be complete by the end of the first half of 2016.  Olaratumab is a human IgG1 monoclonal antibody that is being developed for the treatment of sarcoma.
http://seekingalpha....
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
May 04, 2016
Occurred Source:
http://lilly.mediaroom.com/index.php?s=9042&item=137539
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Olaratumab, Sarcoma, Fda Rolling Submission, Nda Filing
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.